At a glance

Eloralintide Quick Reference

Clinical range: 1–9mg weekly
Fixed-dose Phase 2 arms; not a starting recommendation
Trial duration: 48 weeks
Randomized Phase 2 study in 263 adults
Route: SubQ Injection
Once weekly in published research
Research target: Amylin receptors
Satiety and meal-size signaling

Overview

What Is Eloralintide?

Eloralintide, previously called LY3841136 and informally shortened to Elora, is an investigational long-acting amylin-receptor agonist developed by Eli Lilly. It has been studied as a once-weekly subcutaneous treatment for obesity and related metabolic conditions.

Amylin is released by the pancreas alongside insulin. It contributes to fullness, meal-size control, and gastric emptying. Eloralintide selectively targets this pathway rather than acting as a GLP-1, GIP, or glucagon agonist.

The main published clinical signal is a 48-week randomized Phase 2 study in 263 adults with obesity or overweight and a related comorbidity, without type 2 diabetes. Phase 3 trials are ongoing, but Eloralintide remains investigational.

Mechanism

Eloralintide Mechanism of Action

Amylin-receptor activation

Eloralintide is designed as a long-acting selective agonist of amylin receptors.

Satiety signaling

Amylin-pathway signals contribute to fullness and smaller meals, reducing energy intake.

Gastric emptying

Amylin biology can slow gastric emptying, extending fullness while also contributing to GI adverse effects.

Selective program

The compound was designed to reduce off-target calcitonin-receptor activity compared with less selective amylin analogs.

Research findings

Eloralintide Benefits

The strongest evidence is the 48-week randomized Phase 2 study. These outcomes were measured under trial conditions and cannot validate an unverified RUO product.

Dose-Dependent Weight Loss

Mean weight reduction ranged from 9.5% at 1mg to 20.1% at 9mg after 48 weeks, compared with 0.4% for placebo.

Satiety and Intake

The intended effect is lower calorie intake through amylin-mediated fullness and meal-size signaling.

Waist and BMI

The Phase 2 study reported improvements in waist circumference and body-mass index alongside weight reduction.

Cardiometabolic Markers

Reported changes included blood pressure, lipids, glycemic markers, and inflammation measures; long-term clinical outcomes remain unknown.

Protocol planning

Eloralintide Dosing Protocol

The once-weekly ranges below come from Phase 2 trial arms, not from an approved protocol. A low-end community start of 500mcg is anecdotal and has not been validated by the trial.

Members Access Only

Sign in or create a free account to view this content.

Preparation

Eloralintide Reconstitution

Example concentration

Example: 10mg vial + 2mL compatible diluent

Result5mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add diluent slowly

Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.

3

Dissolve gently

Swirl or roll the vial until the contents dissolve; do not shake.

4

Store

Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.

N=1 reports

Eloralintide Community Experience

Self-reported early community experiences are sparse and cannot establish product identity, efficacy, or safety.

Positive Reports

Early users describe quieter appetite and smaller meals rather than stimulant-like energy.
Some describe a smoother appetite profile than expected from incretin compounds, though direct comparisons are unreliable.
Interest has grown around the 48-week Phase 2 weight-loss result.

Negative & Mixed Reports

Nausea, early fullness, fatigue, and reduced food tolerance recur in reports.
Many community reports cannot verify product identity or actual dose.
Combining an amylin agonist with an incretin can complicate hydration, adequate food intake, and side-effect attribution.

Stacking & synergy

Eloralintide Stacking & Synergy

These are research pairings, not established self-directed stacks. Amylin and incretin pathways differ, but combination tolerability requires direct clinical evidence.

Eloralintide + Tirzepatide

Lilly is studying this combination. Separate monotherapy results cannot predict its final efficacy or tolerability.

Eloralintide + Retatrutide

The pairing is mechanistically interesting but unvalidated. Overlapping appetite and GI effects could make nutrition and tolerability harder to manage.

Eloralintide + Cagrilintide

Both engage the amylin pathway. The combination is redundant in concept and lacks clinical evidence.

Safety notes

Eloralintide Side Effects & Safety

In Phase 2, gastrointestinal symptoms and fatigue were the most common adverse events. Higher-dose arms had more events; slower escalation improved tolerability. Phase 2 does not establish long-term safety or the safety of unverified RUO products.

Persistent vomiting, severe abdominal pain, inability to hydrate, or signs of a serious allergic reaction warrant prompt medical evaluation.

Common Trial Events

Nausea, early fullness, vomiting, constipation, or diarrhea.
Fatigue and reduced food tolerance.
Injection-site irritation.

Monitoring Concerns

Inadequate fluid, protein, or electrolyte intake.
Fainting, confusion, severe weakness, or low-blood-sugar symptoms.
Rapid weight loss with strength or lean-mass decline.

Eloralintide Precautions

Avoid or Discuss With a Clinician If

Pregnancy or breastfeeding; reproductive safety is not established.
The product has no credible identity, purity, or sterility testing.
You have an acute GI, pancreatic, gallbladder, metabolic, liver, kidney, or cardiovascular illness requiring evaluation.

Use Caution With

GLP-1 agonists, tirzepatide, retatrutide, cagrilintide, insulin, or other glucose-lowering drugs.
Gastroparesis, chronic nausea, or prior GI intolerance.
An eating-disorder history or difficulty maintaining protein and hydration.

Eloralintide is investigational and not FDA approved. Phase 3 studies are ongoing.

Final verdict

Peptide Protocols Verdict on Eloralintide

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our opinionated opinion

Eloralintide is the newest high-profile compound to enter the peptide space, and interest spiked as soon as RUO vendors began listing it.

Phase 2 human data offer some reassurance on efficacy and tolerability, but they do not establish long-term safety. More critically, we cannot yet be confident that current research-grade material matches the compound and formulation used in clinical trials. Analytical methods are still maturing given how recently Eloralintide appeared, and at least one testing lab has told us they are not fully confident in their assays for it. At present, only one of our vetted suppliers carries the product.

Our stance remains cautious. We will revise this view as better analytical methods, additional clinical data, and meaningful real-world experience become available.